<DOC>
	<DOCNO>NCT00240045</DOCNO>
	<brief_summary>We address hypothesis refractory ascites Type 2 hepatorenal syndrome mediate part diminish circulatory volume treatment midodrine , octreotide albumin improve renal patient outcome restore effective circulating volume systemic perfusion . Our primary objective ass change creatinine clearance use inulin . We enroll 15 patient Type 2 hepatorenal syndrome refractory ascites inclusion exclusion criterion satisfy . They treat 1 month octreotide LAR , albumin midodrine . Renal , serum neurohormonal parameter measure , , initiation drug compare .</brief_summary>
	<brief_title>The Use Drugs Improve Kidney Function Patients With Liver Kidney Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Hepatorenal Syndrome</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Midodrine</mesh_term>
	<criteria>Cirrhosis ( biopsy compatible clinical ( ascites , varix ) , laboratory ( low albumin , elevate bilirubin , elevate INR ) radiologic data ( nodular appear liver ultrasound ) ) . Type 2 hepatorenal syndrome and/or refractory ascites Secondary cause renal dysfunction ( proteinuria &gt; 500 mg/day , active urinary sediment , abnormal renal ultrasound , nephrotoxic medication ) Bacterial infection ( positive blood , urine ascites culture ) within past 2 week Gastrointestinal hemorrhage encephalopathy within past 2 week Age &lt; 18 Transvenous intrahepatic portosystemic stent shunt ( TIPS ) Hepatocellular carcinoma beyond Milan criterion</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>Hepatorenal syndrome</keyword>
	<keyword>Refractory ascites</keyword>
	<keyword>Midodrine</keyword>
	<keyword>Octreotide</keyword>
	<keyword>Albumin</keyword>
	<keyword>Cirrhosis</keyword>
</DOC>